ATE374817T1 - Krebszellen-impfstoff - Google Patents
Krebszellen-impfstoffInfo
- Publication number
- ATE374817T1 ATE374817T1 AT99961831T AT99961831T ATE374817T1 AT E374817 T1 ATE374817 T1 AT E374817T1 AT 99961831 T AT99961831 T AT 99961831T AT 99961831 T AT99961831 T AT 99961831T AT E374817 T1 ATE374817 T1 AT E374817T1
- Authority
- AT
- Austria
- Prior art keywords
- protein
- specific regulator
- mhc class
- rna molecule
- molecule encoding
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 229940030156 cell vaccine Drugs 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000014616 translation Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 abstract 1
- 101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 abstract 1
- 101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 abstract 1
- 101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 abstract 1
- 102000043131 MHC class II family Human genes 0.000 abstract 1
- 108091054438 MHC class II family Proteins 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000004957 immunoregulator effect Effects 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 238000001243 protein synthesis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/205,995 US6368855B1 (en) | 1996-06-11 | 1998-12-04 | MHC class II antigen presenting cells containing oligonucleotides which inhibit Ii protein expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE374817T1 true ATE374817T1 (de) | 2007-10-15 |
Family
ID=22764546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99961831T ATE374817T1 (de) | 1998-12-04 | 1999-11-24 | Krebszellen-impfstoff |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6368855B1 (de) |
| EP (1) | EP1135482B1 (de) |
| JP (1) | JP4836327B2 (de) |
| KR (1) | KR100689429B1 (de) |
| CN (1) | CN100389196C (de) |
| AT (1) | ATE374817T1 (de) |
| AU (1) | AU771580C (de) |
| CA (1) | CA2354188C (de) |
| DE (1) | DE69937252D1 (de) |
| WO (1) | WO2000034467A1 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060008448A1 (en) * | 1996-06-11 | 2006-01-12 | Minzhen Xu | Inhibition of li expression in mammalian cells |
| US20030198626A1 (en) * | 2002-04-22 | 2003-10-23 | Antigen Express, Inc. | Inhibition of Ii expression in mammalian cells |
| EP1270732A1 (de) * | 2001-06-21 | 2003-01-02 | Schuler, Gerold | Transfektion von eukaryotischen Zellen mit linearen Polynukleotiden mittels Elektroporation |
| US20030206916A1 (en) | 2002-05-03 | 2003-11-06 | Rush-Presbyterian-St. Luke's Medical Center | Immunogenic peptides |
| US11243494B2 (en) | 2002-07-31 | 2022-02-08 | Abs Global, Inc. | Multiple laminar flow-based particle and cellular separation with laser steering |
| AU2003278709A1 (en) * | 2002-08-14 | 2004-03-03 | Duke University | Method of enhancing cd4+ t cell responses |
| US20060172315A1 (en) * | 2005-02-01 | 2006-08-03 | Anderson Amy L | Methods for staining cells for identification and sorting |
| US20060265485A1 (en) * | 2005-05-17 | 2006-11-23 | Chai Sek M | Method and apparatus for controlling data transfer in a processing system |
| US7603492B2 (en) * | 2005-09-20 | 2009-10-13 | Motorola, Inc. | Automatic generation of streaming data interface circuit |
| JP5425474B2 (ja) * | 2006-01-26 | 2014-02-26 | アイシス ファーマシューティカルズ， インコーポレーテッド | ハンチンチン対する、組成物及びその使用 |
| US20080120497A1 (en) * | 2006-11-20 | 2008-05-22 | Motorola, Inc. | Automated configuration of a processing system using decoupled memory access and computation |
| EP2139908A4 (de) * | 2007-03-12 | 2011-02-16 | Antigen Express Inc | Li-suppression unter beteiligung von li-rnai in der krebs-immuntherapie |
| US10908066B2 (en) | 2010-11-16 | 2021-02-02 | 1087 Systems, Inc. | Use of vibrational spectroscopy for microfluidic liquid measurement |
| US8961904B2 (en) | 2013-07-16 | 2015-02-24 | Premium Genetics (Uk) Ltd. | Microfluidic chip |
| US11796449B2 (en) | 2013-10-30 | 2023-10-24 | Abs Global, Inc. | Microfluidic system and method with focused energy apparatus |
| HK1248809A1 (zh) | 2015-02-19 | 2018-10-19 | 1087 Systems, Inc. | 扫描红外线测量系统 |
| EP3796998A1 (de) | 2018-05-23 | 2021-03-31 | ABS Global, Inc. | Systeme und verfahren zur teilchenfokussierung in mikrokanälen |
| CN113260848B (zh) | 2018-12-21 | 2025-04-01 | Abs全球公司 | 亚群识别的系统和方法 |
| WO2020215011A1 (en) | 2019-04-18 | 2020-10-22 | Abs Global, Inc. | System and process for continuous addition of cryoprotectant |
| US11628439B2 (en) | 2020-01-13 | 2023-04-18 | Abs Global, Inc. | Single-sheath microfluidic chip |
| EP4232601A4 (de) | 2020-10-21 | 2024-10-09 | ABS Global, Inc. | Verfahren und systeme zur verarbeitung genetischer proben zur bestimmung der identität oder zum nachweis von kontamination |
| EP4248190A4 (de) | 2020-11-23 | 2024-12-25 | ABS Global, Inc. | Modulare durchflusszytometriesysteme und verfahren zur verarbeitung von proben |
| USD1118965S1 (en) | 2021-11-12 | 2026-03-17 | Abs Global, Inc. | Flow cytometry device |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5514788A (en) * | 1993-05-17 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
| US5442049A (en) * | 1992-11-19 | 1995-08-15 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating the effects of cytomegalovirus infections |
| US5965722A (en) * | 1991-05-21 | 1999-10-12 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ras gene with chimeric and alternating oligonucleotides |
| US5858776A (en) * | 1993-11-03 | 1999-01-12 | Repligen Corporation | Tumor cells with increased immunogenicity and uses therefor |
| US5726020A (en) | 1996-06-11 | 1998-03-10 | University Of Massachusetts | Inhibition of II synthesis |
| KR20000065204A (ko) * | 1997-03-07 | 2000-11-06 | 모치다 에이 | Cd14에 대한 안티센스 화합물 |
| CA2288946A1 (en) * | 1997-05-05 | 1998-11-12 | Hoechst Marion Roussel Deutschland Gmbh | Modified antisense nucleotides complementary to a section of the human ha-ras gene |
| US5945290A (en) * | 1998-09-18 | 1999-08-31 | Isis Pharmaceuticals, Inc. | Antisense modulation of RhoA expression |
-
1998
- 1998-12-04 US US09/205,995 patent/US6368855B1/en not_active Expired - Lifetime
-
1999
- 1999-11-24 KR KR1020017006994A patent/KR100689429B1/ko not_active Expired - Fee Related
- 1999-11-24 CA CA2354188A patent/CA2354188C/en not_active Expired - Lifetime
- 1999-11-24 AT AT99961831T patent/ATE374817T1/de not_active IP Right Cessation
- 1999-11-24 DE DE69937252T patent/DE69937252D1/de not_active Expired - Lifetime
- 1999-11-24 CN CNB998153788A patent/CN100389196C/zh not_active Expired - Fee Related
- 1999-11-24 JP JP2000586901A patent/JP4836327B2/ja not_active Expired - Fee Related
- 1999-11-24 AU AU18329/00A patent/AU771580C/en not_active Ceased
- 1999-11-24 WO PCT/US1999/028096 patent/WO2000034467A1/en not_active Ceased
- 1999-11-24 EP EP99961831A patent/EP1135482B1/de not_active Expired - Lifetime
-
2002
- 2002-01-22 US US10/054,387 patent/US20030054365A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000034467A1 (en) | 2000-06-15 |
| KR100689429B1 (ko) | 2007-03-08 |
| KR20010089545A (ko) | 2001-10-06 |
| EP1135482A1 (de) | 2001-09-26 |
| US20030054365A1 (en) | 2003-03-20 |
| JP2002531582A (ja) | 2002-09-24 |
| CN100389196C (zh) | 2008-05-21 |
| US6368855B1 (en) | 2002-04-09 |
| CA2354188A1 (en) | 2000-06-15 |
| CN1332799A (zh) | 2002-01-23 |
| AU771580C (en) | 2005-08-04 |
| DE69937252D1 (de) | 2007-11-15 |
| AU1832900A (en) | 2000-06-26 |
| AU771580B2 (en) | 2004-03-25 |
| EP1135482A4 (de) | 2002-11-06 |
| EP1135482B1 (de) | 2007-10-03 |
| JP4836327B2 (ja) | 2011-12-14 |
| CA2354188C (en) | 2013-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE374817T1 (de) | Krebszellen-impfstoff | |
| Raben et al. | A motif in human histidyl-tRNA synthetase which is shared among several aminoacyl-tRNA synthetases is a coiled-coil that is essential for enzymatic activity and contains the major autoantigenic epitope. | |
| Sæterdal et al. | Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer | |
| Kocher et al. | Identification and intracellular location of MAGE-3 gene product | |
| Timpte et al. | Porcine submaxillary gland apomucin contains tandemly repeated, identical sequences of 81 residues. | |
| DK1137792T3 (da) | En rekombinant vektor, der udtrykker adskillige costimulatoriske molekyler, og anvendelser deraf | |
| AU2018351481A1 (en) | Novel artificial nucleic acid molecules | |
| BR9914374A (pt) | Sequências genÈmicas de neisseria e métodos para seu uso | |
| EP1009814A4 (de) | Kdr, ein menschlicher tyrosin kinase rezeptor | |
| ATE471373T1 (de) | Expression von endogenen genen durch homologe rekombination eines vektorkonstruktes mit zellulärer dna | |
| RU2218181C2 (ru) | ЧЕЛОВЕЧЕСКИЙ СЕМАФОРИН L(H-Sema-L) И СООТВЕТСТВУЮЩИЕ СЕМАФОРИНЫ В ДРУГИХ ВИДАХ | |
| CA2295321C (en) | Isolated nona- and decapeptides which bind to hla molecules, and the use thereof | |
| DE69840333D1 (de) | 2-m übergang des zellzyklus | |
| HUP9902710A2 (hu) | Rekombináns sertés-poxvírus | |
| EP0796104A4 (de) | Das einbringen von nukleinsäuremolekülen in schleimhautgewebe | |
| DE69927249D1 (de) | Induzierendes alphavirengen- expressionssystem | |
| ES2267812T3 (es) | Materiales y metodos que relacionan respuestas inmunes con proteinas de fusion. | |
| HUP9800613A2 (hu) | Humán Fas-antigén elleni humanizált antitest | |
| Payton et al. | Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity | |
| Toda et al. | DNA vaccine using invariant chain gene for delivery of CD4+ T cell epitope peptide derived from Japanese cedar pollen allergen inhibits allergen‐specific IgE response | |
| US20020193289A1 (en) | Methods and compositions for modulating telomerase reverse transcriptase (TERT) expression | |
| Forconi et al. | Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti‐idiotypic antibody responses | |
| DE69725857D1 (de) | Vektor für polynukleotidimpfstoffe | |
| RU2002103722A (ru) | Белок альтернативной рамки считывания рецептора у Т-клеток(TARP) и его применения | |
| ES2441252T3 (es) | Epítopos promiscuos de linfocitos T CD4 HER-2/NEU |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |